Trial Profile
Phase 1-2a Dose-Ranging Study of TLK286 [canofosfamide] in Combination With Docetaxel (Taxotere) in Platinum-Resistant Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jun 2011
Price :
$35
*
At a glance
- Drugs Canfosfamide (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Sep 2005 New trial record.